Shares of Kura Oncology KURA have rallied 15.5% in the past week against the industry’s decline of 0.1%. Earlier this week, ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

A French pharmaceutical giant is acquiring a Cambridge, Mass. biotech and its rare immunology disease treatment which is ...

Sanofi will gain Blueprint's Ayvakit, a treatment for systemic mastocytosis and gastrointestinal stromal tumors, among other therapies in its pipeline.

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

GISTs are a rare type of cancer that develops in the digestive tract’s connective tissue, specifically from cells that help regulate muscle contractions. GISTs are primarily driven by genetic ...

New York, USA, April 15, 2025 (GLOBE NEWSWIRE) -- Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight ...

Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours.

DelveInsight’s “Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these ...

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial.

Researchers from the University of Colorado Anschutz Medical Campus have identified a new feature indicative of the chance of recurrence of Gastrointestinal Stromal Tumors (GISTs).